Cargando…

Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS

Isolated isochromosome 17q, i(17q), accounts for less than 1% of myeloid neoplasms that are commonly classified as myelodysplastic/myeloproliferative neoplasms, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPN). We have shown previously that these cas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanagal-Shamanna, Rashmi, Luthra, Rajyalakshmi, Yin, Cameron C., Patel, Keyur P., Takahashi, Koichi, Lu, Xinyan, Lee, John, Zhao, Chong, Stingo, Francesco, Zuo, Zhuang, Routbort, Mark J., Singh, Rajesh R., Fox, Patricia, Ravandi, Farhad, Garcia-Manero, Guillermo, Medeiros, L. Jeffrey, Bueso-Ramos, Carlos E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924712/ https://www.ncbi.nlm.nih.gov/pubmed/26883102 http://dx.doi.org/10.18632/oncotarget.7350

Ejemplares similares

Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era
por: Montes-Moreno, Santiago, et al.
Publicado: (2018)

Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia
por: Cui, Yajuan, et al.
Publicado: (2015)

Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms
por: Zuo, Zhuang, et al.
Publicado: (2022)

P729: LANDSCAPE OF GERMLINE PATHOGENIC/ LIKELY PATHOGENIC MUTATIONS INVOLVING DNA REPAIR GENES IN SOLID TUMOR PATIENTS WITH ANTECEDENT OR SUBSEQUENT MYELOID NEOPLASMS
por: Hein, Kimberly, et al.
Publicado: (2023)

Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2017)

Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations
por: Loghavi, Sanam, et al.
Publicado: (2014)

Myelodysplastic/ Myeloproliferative Neoplasms-Unclassifiable (MDS/MPN-U) with Isolated Isochromosome 17q Represents a Distinct Clinico-Biologic Subset: A Multi-institutional Collaborative Study from the Bone Marrow Pathology Group
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2022)

SETBP1 Mutations Drive Leukemic Transformation in ASXL1-Mutated MDS
por: Inoue, Daichi, et al.
Publicado: (2014)

RAS and TP53 can predict survival in adults with T‐cell lymphoblastic leukemia treated with hyper‐CVAD
por: Sakhdari, Ali, et al.
Publicado: (2019)

Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia
por: Ok, Chi Young, et al.
Publicado: (2019)

Incidental identification of inv(16)(p13.1q22)/CBFB–MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy
por: Quesada, Andrés E., et al.
Publicado: (2021)

Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing
por: Quesada, Andrés E., et al.
Publicado: (2018)

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia
por: Bidikian, Aram, et al.
Publicado: (2022)

CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia
por: Qian, Yi, et al.
Publicado: (2021)

ASXL1 and SETBP1 mutations promote leukaemogenesis by repressing TGFβ pathway genes through histone deacetylation
por: Saika, Makoto, et al.
Publicado: (2018)

Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray
por: Chen, Hui, et al.
Publicado: (2017)

P583: PROGNOSTIC IMPLICATIONS OF WT1 MUTATIONS IN PATIENTS WITH DE NOVO AND RELAPSED ACUTE MYELOID LEUKEMIA IN THE ERA OF NOVEL TARGETED THERAPIES
por: Atluri, Himachandana, et al.
Publicado: (2023)

High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance
por: Yang, Hui, et al.
Publicado: (2022)

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2021)

Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia
por: Ouyang, Yuan, et al.
Publicado: (2017)

Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations
por: Bannon, Sarah A., et al.
Publicado: (2021)

SETBP1 dysregulation in congenital disorders and myeloid neoplasms
por: Coccaro, Nicoletta, et al.
Publicado: (2017)

P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE
por: Urrutia, Samuel, et al.
Publicado: (2023)

TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases
por: Ok, Chi Young, et al.
Publicado: (2015)

Identification of a novel de novo mutation of SETBP1 and new findings of SETBP1 in tumorgenesis
por: Wang, Hongdan, et al.
Publicado: (2023)

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia
por: Tashakori, Mehrnoosh, et al.
Publicado: (2022)

Biomarkers in Acute Myeloid Leukemia: Leveraging Next Generation Sequencing Data for Optimal Therapeutic Strategies
por: El Achi, Hanadi, et al.
Publicado: (2021)

Alteration of the SETBP1 Gene and Splicing Pathway Genes SF3B1, U2AF1, and SRSF2 in Childhood Acute Myeloid Leukemia
por: Choi, Hyun-Woo, et al.
Publicado: (2015)

IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
por: DiNardo, Courtney D, et al.
Publicado: (2015)

Over-Expression of CYP2E1 mRNA and Protein: Implications of Xenobiotic Induced Damage in Patients with De Novo Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFβ-MYH11
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2012)

Isochromosome 17q in Chronic Lymphocytic Leukemia
por: Alhourani, Eyad, et al.
Publicado: (2015)

P509: THE IMPACT OF THE NUMBER OF RAS MUTATIONS IN THE OUTCOMES OF PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED FRONTLINE AT A SINGLE INSTITUTION.
por: Swaminathan, Mahesh, et al.
Publicado: (2023)

Somatic SETBP1 mutations in myeloid malignancies
por: Makishima, Hideki, et al.
Publicado: (2013)

P743: CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
por: Urrutia, Samuel, et al.
Publicado: (2023)

Myeloid Neoplasms with Isolated Isochromosome 17q: a yet to be Defined Entity
por: Lamprianidou, Eleftheria, et al.
Publicado: (2017)

SETBP1 mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome
por: Linder, Katherine, et al.
Publicado: (2017)

Isochromosome Mosaic Turner Syndrome: A Case Report
por: Llanes, Mark Ramon Victor, et al.
Publicado: (2019)

Prognostic significance of isochromosome 17q in hematologic malignancies
por: Koczkodaj, Dorota, et al.
Publicado: (2021)

Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory
por: Mehrotra, Meenakshi, et al.
Publicado: (2017)

S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Bataller, Alex, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nf216iuiah67pb75eno7khdapc